text
stringlengths 666
1.72k
|
|---|
{"patient_id":"ANODE_SYNTH_2025_001","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":86,"sex":"female","bmi":36.2,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-05-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-32},"pfs_months":24.08},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-06-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.9,"censored":false},"longitudinal_labs":[{"date":"2020-04-06","hemoglobin_g_dL":14.0,"wbc_k_uL":8.5,"platelets_k_uL":197,"creatinine_mg_dL":0.94,"alt_U_L":15},{"date":"2020-11-23","hemoglobin_g_dL":13.9,"wbc_k_uL":6.6,"platelets_k_uL":176,"creatinine_mg_dL":1.32,"alt_U_L":45},{"date":"2022-06-12","hemoglobin_g_dL":13.0,"wbc_k_uL":5.9,"platelets_k_uL":339,"creatinine_mg_dL":1.1,"alt_U_L":114}]}
|
{"patient_id":"ANODE_SYNTH_2025_002","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":83,"sex":"female","bmi":33.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["brain","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-06-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-58},"pfs_months":27.14},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-21","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.2,"censored":true},"longitudinal_labs":[{"date":"2023-05-05","hemoglobin_g_dL":14.4,"wbc_k_uL":8.8,"platelets_k_uL":426,"creatinine_mg_dL":1.09,"alt_U_L":58},{"date":"2023-12-21","hemoglobin_g_dL":12.1,"wbc_k_uL":5.3,"platelets_k_uL":164,"creatinine_mg_dL":1.59,"alt_U_L":100},{"date":"2025-11-21","hemoglobin_g_dL":9.8,"wbc_k_uL":4.3,"platelets_k_uL":130,"creatinine_mg_dL":0.86,"alt_U_L":105}]}
|
{"patient_id":"ANODE_SYNTH_2025_003","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":72,"sex":"female","bmi":30.1,"smoking_pack_years":12,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-10-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-48},"pfs_months":30.26},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-07-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":52.4,"censored":false},"longitudinal_labs":[{"date":"2024-08-28","hemoglobin_g_dL":14.7,"wbc_k_uL":7.1,"platelets_k_uL":191,"creatinine_mg_dL":0.65,"alt_U_L":28},{"date":"2025-04-24","hemoglobin_g_dL":11.1,"wbc_k_uL":8.4,"platelets_k_uL":351,"creatinine_mg_dL":1.31,"alt_U_L":75},{"date":"2027-07-02","hemoglobin_g_dL":11.5,"wbc_k_uL":6.6,"platelets_k_uL":198,"creatinine_mg_dL":1.88,"alt_U_L":134}]}
|
{"patient_id":"ANODE_SYNTH_2025_004","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.9,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":68,"sex":"female","bmi":27.3,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-07-11","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-75},"pfs_months":32.0},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.3,"censored":false},"longitudinal_labs":[{"date":"2022-05-13","hemoglobin_g_dL":11.8,"wbc_k_uL":9.9,"platelets_k_uL":344,"creatinine_mg_dL":0.76,"alt_U_L":25},{"date":"2023-01-07","hemoglobin_g_dL":14.0,"wbc_k_uL":7.5,"platelets_k_uL":351,"creatinine_mg_dL":1.07,"alt_U_L":55},{"date":"2025-04-18","hemoglobin_g_dL":10.3,"wbc_k_uL":7.9,"platelets_k_uL":321,"creatinine_mg_dL":1.7,"alt_U_L":40}]}
|
{"patient_id":"ANODE_SYNTH_2025_005","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":7.2,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":87,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.7,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-83},"pfs_months":14.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-10-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.4,"censored":true},"longitudinal_labs":[{"date":"2021-04-14","hemoglobin_g_dL":13.9,"wbc_k_uL":5.2,"platelets_k_uL":328,"creatinine_mg_dL":0.94,"alt_U_L":34},{"date":"2021-12-12","hemoglobin_g_dL":10.1,"wbc_k_uL":7.5,"platelets_k_uL":279,"creatinine_mg_dL":1.2,"alt_U_L":17},{"date":"2022-10-26","hemoglobin_g_dL":10.5,"wbc_k_uL":3.7,"platelets_k_uL":100,"creatinine_mg_dL":1.97,"alt_U_L":90}]}
|
{"patient_id":"ANODE_SYNTH_2025_006","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":65,"sex":"male","bmi":28.2,"smoking_pack_years":73,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.1,"metastatic_sites":["liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-07-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-32},"pfs_months":15.67},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-12-29","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":19.6,"censored":true},"longitudinal_labs":[{"date":"2022-07-02","hemoglobin_g_dL":13.8,"wbc_k_uL":5.7,"platelets_k_uL":318,"creatinine_mg_dL":1.09,"alt_U_L":16},{"date":"2023-01-16","hemoglobin_g_dL":11.3,"wbc_k_uL":4.4,"platelets_k_uL":272,"creatinine_mg_dL":0.91,"alt_U_L":76},{"date":"2023-12-29","hemoglobin_g_dL":9.9,"wbc_k_uL":4.2,"platelets_k_uL":321,"creatinine_mg_dL":1.87,"alt_U_L":107}]}
|
{"patient_id":"ANODE_SYNTH_2025_007","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":62,"sex":"female","bmi":28.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["liver","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-11-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-59},"pfs_months":38.6},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-20","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":54.5,"censored":false},"longitudinal_labs":[{"date":"2022-09-04","hemoglobin_g_dL":14.3,"wbc_k_uL":6.5,"platelets_k_uL":215,"creatinine_mg_dL":0.74,"alt_U_L":34},{"date":"2023-05-12","hemoglobin_g_dL":10.6,"wbc_k_uL":8.1,"platelets_k_uL":320,"creatinine_mg_dL":1.43,"alt_U_L":98},{"date":"2026-02-20","hemoglobin_g_dL":11.8,"wbc_k_uL":6.8,"platelets_k_uL":341,"creatinine_mg_dL":0.96,"alt_U_L":143}]}
|
{"patient_id":"ANODE_SYNTH_2025_008","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":68,"sex":"female","bmi":37.6,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-06-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-59,"peak_response_20wk_change_percent":-49},"pfs_months":28.58},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-12-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.7,"censored":false},"longitudinal_labs":[{"date":"2022-04-06","hemoglobin_g_dL":12.2,"wbc_k_uL":10.0,"platelets_k_uL":169,"creatinine_mg_dL":0.76,"alt_U_L":12},{"date":"2022-12-09","hemoglobin_g_dL":11.5,"wbc_k_uL":8.0,"platelets_k_uL":354,"creatinine_mg_dL":1.13,"alt_U_L":68},{"date":"2024-12-12","hemoglobin_g_dL":12.8,"wbc_k_uL":6.1,"platelets_k_uL":241,"creatinine_mg_dL":1.86,"alt_U_L":42}]}
|
{"patient_id":"ANODE_SYNTH_2025_009","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.3,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":82,"sex":"male","bmi":25.3,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-10-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-84},"pfs_months":42.09},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-05-09","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":65.1,"censored":true},"longitudinal_labs":[{"date":"2024-08-06","hemoglobin_g_dL":12.1,"wbc_k_uL":8.3,"platelets_k_uL":408,"creatinine_mg_dL":0.65,"alt_U_L":65},{"date":"2025-04-12","hemoglobin_g_dL":11.1,"wbc_k_uL":5.8,"platelets_k_uL":379,"creatinine_mg_dL":1.41,"alt_U_L":24},{"date":"2028-05-09","hemoglobin_g_dL":10.8,"wbc_k_uL":5.9,"platelets_k_uL":184,"creatinine_mg_dL":1.53,"alt_U_L":129}]}
|
{"patient_id":"ANODE_SYNTH_2025_010","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":13.0,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":66,"sex":"female","bmi":27.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["bone","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-52},"pfs_months":20.11},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-09","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2024-12-14","hemoglobin_g_dL":14.5,"wbc_k_uL":6.1,"platelets_k_uL":220,"creatinine_mg_dL":1.19,"alt_U_L":62},{"date":"2025-07-19","hemoglobin_g_dL":12.2,"wbc_k_uL":8.5,"platelets_k_uL":310,"creatinine_mg_dL":1.3,"alt_U_L":19},{"date":"2026-11-09","hemoglobin_g_dL":10.1,"wbc_k_uL":4.8,"platelets_k_uL":203,"creatinine_mg_dL":1.7,"alt_U_L":50}]}
|
{"patient_id":"ANODE_SYNTH_2025_011","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":56,"sex":"female","bmi":34.1,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-11-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-32},"pfs_months":25.76},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":47.2,"censored":true},"longitudinal_labs":[{"date":"2021-10-27","hemoglobin_g_dL":13.8,"wbc_k_uL":9.1,"platelets_k_uL":190,"creatinine_mg_dL":0.68,"alt_U_L":21},{"date":"2022-05-15","hemoglobin_g_dL":12.8,"wbc_k_uL":8.3,"platelets_k_uL":321,"creatinine_mg_dL":1.56,"alt_U_L":80},{"date":"2024-03-03","hemoglobin_g_dL":11.8,"wbc_k_uL":6.1,"platelets_k_uL":171,"creatinine_mg_dL":1.04,"alt_U_L":62}]}
|
{"patient_id":"ANODE_SYNTH_2025_012","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.0,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":69,"sex":"male","bmi":18.7,"smoking_pack_years":76,"ecog_performance_status":2,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-39},"pfs_months":21.59},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-04-13","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2025-05-20","hemoglobin_g_dL":12.4,"wbc_k_uL":6.6,"platelets_k_uL":202,"creatinine_mg_dL":0.64,"alt_U_L":38},{"date":"2025-11-30","hemoglobin_g_dL":13.5,"wbc_k_uL":8.4,"platelets_k_uL":184,"creatinine_mg_dL":1.06,"alt_U_L":97},{"date":"2027-04-13","hemoglobin_g_dL":10.3,"wbc_k_uL":4.4,"platelets_k_uL":252,"creatinine_mg_dL":1.35,"alt_U_L":40}]}
|
{"patient_id":"ANODE_SYNTH_2025_013","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.3,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":48,"sex":"male","bmi":31.9,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["liver","pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-09-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-70},"pfs_months":30.98},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-06-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":44.8,"censored":false},"longitudinal_labs":[{"date":"2020-07-19","hemoglobin_g_dL":15.1,"wbc_k_uL":5.9,"platelets_k_uL":322,"creatinine_mg_dL":0.78,"alt_U_L":76},{"date":"2021-03-25","hemoglobin_g_dL":10.3,"wbc_k_uL":8.9,"platelets_k_uL":155,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2023-06-23","hemoglobin_g_dL":12.1,"wbc_k_uL":3.2,"platelets_k_uL":307,"creatinine_mg_dL":1.12,"alt_U_L":69}]}
|
{"patient_id":"ANODE_SYNTH_2025_014","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":17.9,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":48,"sex":"female","bmi":28.4,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-08-18","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-47},"pfs_months":28.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-02-16","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.2,"censored":true},"longitudinal_labs":[{"date":"2023-07-23","hemoglobin_g_dL":15.2,"wbc_k_uL":8.8,"platelets_k_uL":322,"creatinine_mg_dL":0.84,"alt_U_L":62},{"date":"2024-02-14","hemoglobin_g_dL":10.2,"wbc_k_uL":4.0,"platelets_k_uL":256,"creatinine_mg_dL":1.46,"alt_U_L":99},{"date":"2026-02-16","hemoglobin_g_dL":9.6,"wbc_k_uL":7.1,"platelets_k_uL":344,"creatinine_mg_dL":1.24,"alt_U_L":100}]}
|
{"patient_id":"ANODE_SYNTH_2025_015","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":69,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-82},"pfs_months":22.05},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-12-29","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.7,"censored":false},"longitudinal_labs":[{"date":"2024-11-16","hemoglobin_g_dL":14.1,"wbc_k_uL":7.7,"platelets_k_uL":424,"creatinine_mg_dL":0.92,"alt_U_L":13},{"date":"2025-07-23","hemoglobin_g_dL":12.0,"wbc_k_uL":5.1,"platelets_k_uL":149,"creatinine_mg_dL":1.16,"alt_U_L":15},{"date":"2026-12-29","hemoglobin_g_dL":12.8,"wbc_k_uL":3.2,"platelets_k_uL":242,"creatinine_mg_dL":1.18,"alt_U_L":98}]}
|
{"patient_id":"ANODE_SYNTH_2025_016","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-09-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-62},"pfs_months":11.07},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-10-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":24.0,"censored":false},"longitudinal_labs":[{"date":"2020-09-05","hemoglobin_g_dL":14.4,"wbc_k_uL":10.2,"platelets_k_uL":209,"creatinine_mg_dL":0.62,"alt_U_L":60},{"date":"2021-03-22","hemoglobin_g_dL":11.7,"wbc_k_uL":7.4,"platelets_k_uL":376,"creatinine_mg_dL":1.38,"alt_U_L":33},{"date":"2021-10-25","hemoglobin_g_dL":11.2,"wbc_k_uL":5.8,"platelets_k_uL":213,"creatinine_mg_dL":1.12,"alt_U_L":38}]}
|
{"patient_id":"ANODE_SYNTH_2025_017","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.4,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":88,"sex":"female","bmi":37.6,"smoking_pack_years":33,"ecog_performance_status":1,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-05-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-41},"pfs_months":11.27},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":15.4,"censored":false},"longitudinal_labs":[{"date":"2025-04-23","hemoglobin_g_dL":14.5,"wbc_k_uL":8.8,"platelets_k_uL":281,"creatinine_mg_dL":0.89,"alt_U_L":13},{"date":"2025-11-11","hemoglobin_g_dL":13.7,"wbc_k_uL":5.0,"platelets_k_uL":331,"creatinine_mg_dL":1.13,"alt_U_L":120},{"date":"2026-05-28","hemoglobin_g_dL":10.7,"wbc_k_uL":5.7,"platelets_k_uL":281,"creatinine_mg_dL":1.18,"alt_U_L":171}]}
|
{"patient_id":"ANODE_SYNTH_2025_018","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":17},"baseline_clinical":{"age":51,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-03-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-79},"pfs_months":19.61},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-11-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":29.6,"censored":true},"longitudinal_labs":[{"date":"2024-01-16","hemoglobin_g_dL":13.3,"wbc_k_uL":4.6,"platelets_k_uL":150,"creatinine_mg_dL":1.22,"alt_U_L":29},{"date":"2024-09-13","hemoglobin_g_dL":10.4,"wbc_k_uL":6.7,"platelets_k_uL":140,"creatinine_mg_dL":1.0,"alt_U_L":72},{"date":"2025-11-21","hemoglobin_g_dL":11.8,"wbc_k_uL":3.5,"platelets_k_uL":237,"creatinine_mg_dL":0.92,"alt_U_L":83}]}
|
{"patient_id":"ANODE_SYNTH_2025_019","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.6,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":68,"sex":"male","bmi":20.8,"smoking_pack_years":72,"ecog_performance_status":0,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.2,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-12-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-32},"pfs_months":11.33},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":15.3,"censored":false},"longitudinal_labs":[{"date":"2022-11-12","hemoglobin_g_dL":11.9,"wbc_k_uL":9.4,"platelets_k_uL":439,"creatinine_mg_dL":0.88,"alt_U_L":21},{"date":"2023-06-12","hemoglobin_g_dL":12.4,"wbc_k_uL":7.4,"platelets_k_uL":260,"creatinine_mg_dL":1.12,"alt_U_L":72},{"date":"2024-01-13","hemoglobin_g_dL":12.6,"wbc_k_uL":3.9,"platelets_k_uL":243,"creatinine_mg_dL":1.44,"alt_U_L":126}]}
|
{"patient_id":"ANODE_SYNTH_2025_020","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.5,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":67,"sex":"female","bmi":35.2,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-06-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-45},"pfs_months":16.79},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-12-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":26.4,"censored":false},"longitudinal_labs":[{"date":"2021-05-22","hemoglobin_g_dL":12.6,"wbc_k_uL":7.6,"platelets_k_uL":317,"creatinine_mg_dL":1.17,"alt_U_L":55},{"date":"2021-12-25","hemoglobin_g_dL":10.8,"wbc_k_uL":6.0,"platelets_k_uL":183,"creatinine_mg_dL":1.28,"alt_U_L":31},{"date":"2022-12-03","hemoglobin_g_dL":10.5,"wbc_k_uL":5.1,"platelets_k_uL":159,"creatinine_mg_dL":1.22,"alt_U_L":54}]}
|
{"patient_id":"ANODE_SYNTH_2025_021","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.1,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":66,"sex":"male","bmi":37.2,"smoking_pack_years":23,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-10-02","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-48},"pfs_months":48.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-12-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":76.6,"censored":false},"longitudinal_labs":[{"date":"2023-09-04","hemoglobin_g_dL":13.7,"wbc_k_uL":9.0,"platelets_k_uL":319,"creatinine_mg_dL":0.77,"alt_U_L":46},{"date":"2024-03-30","hemoglobin_g_dL":11.2,"wbc_k_uL":7.8,"platelets_k_uL":330,"creatinine_mg_dL":1.05,"alt_U_L":80},{"date":"2027-12-10","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":166,"creatinine_mg_dL":1.56,"alt_U_L":162}]}
|
{"patient_id":"ANODE_SYNTH_2025_022","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":67,"sex":"male","bmi":29.0,"smoking_pack_years":75,"ecog_performance_status":2,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain","pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-28,"peak_response_20wk_change_percent":-46},"pfs_months":20.07},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-02-14","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.8,"censored":true},"longitudinal_labs":[{"date":"2021-02-26","hemoglobin_g_dL":11.9,"wbc_k_uL":6.8,"platelets_k_uL":191,"creatinine_mg_dL":0.96,"alt_U_L":26},{"date":"2021-10-20","hemoglobin_g_dL":11.3,"wbc_k_uL":6.0,"platelets_k_uL":168,"creatinine_mg_dL":0.78,"alt_U_L":26},{"date":"2023-02-14","hemoglobin_g_dL":10.3,"wbc_k_uL":7.8,"platelets_k_uL":181,"creatinine_mg_dL":1.64,"alt_U_L":75}]}
|
{"patient_id":"ANODE_SYNTH_2025_023","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.7,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":60,"sex":"female","bmi":22.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["liver","contralateral lung","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-12-10","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-54},"pfs_months":25.99},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":43.2,"censored":true},"longitudinal_labs":[{"date":"2022-11-13","hemoglobin_g_dL":13.0,"wbc_k_uL":6.2,"platelets_k_uL":380,"creatinine_mg_dL":1.09,"alt_U_L":35},{"date":"2023-06-08","hemoglobin_g_dL":12.1,"wbc_k_uL":7.1,"platelets_k_uL":212,"creatinine_mg_dL":1.16,"alt_U_L":78},{"date":"2025-03-22","hemoglobin_g_dL":12.0,"wbc_k_uL":4.5,"platelets_k_uL":199,"creatinine_mg_dL":1.22,"alt_U_L":34}]}
|
{"patient_id":"ANODE_SYNTH_2025_024","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":63,"sex":"female","bmi":24.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-08-29","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-57,"peak_response_20wk_change_percent":-40},"pfs_months":22.93},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-09-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":34.0,"censored":false},"longitudinal_labs":[{"date":"2025-08-09","hemoglobin_g_dL":14.3,"wbc_k_uL":10.5,"platelets_k_uL":418,"creatinine_mg_dL":0.73,"alt_U_L":62},{"date":"2026-02-25","hemoglobin_g_dL":10.5,"wbc_k_uL":5.6,"platelets_k_uL":285,"creatinine_mg_dL":1.58,"alt_U_L":102},{"date":"2027-09-25","hemoglobin_g_dL":9.7,"wbc_k_uL":3.2,"platelets_k_uL":272,"creatinine_mg_dL":1.09,"alt_U_L":74}]}
|
{"patient_id":"ANODE_SYNTH_2025_025","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":62,"sex":"female","bmi":21.1,"smoking_pack_years":57,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-76},"pfs_months":39.13},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-22","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.6,"censored":true},"longitudinal_labs":[{"date":"2022-02-26","hemoglobin_g_dL":12.2,"wbc_k_uL":7.5,"platelets_k_uL":319,"creatinine_mg_dL":0.64,"alt_U_L":41},{"date":"2022-09-16","hemoglobin_g_dL":10.7,"wbc_k_uL":5.8,"platelets_k_uL":172,"creatinine_mg_dL":0.87,"alt_U_L":60},{"date":"2025-08-22","hemoglobin_g_dL":10.4,"wbc_k_uL":7.3,"platelets_k_uL":115,"creatinine_mg_dL":1.82,"alt_U_L":149}]}
|
{"patient_id":"ANODE_SYNTH_2025_026","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":83,"sex":"female","bmi":36.0,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-02-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-34},"pfs_months":15.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-07-08","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.8,"censored":false},"longitudinal_labs":[{"date":"2020-12-28","hemoglobin_g_dL":13.0,"wbc_k_uL":6.0,"platelets_k_uL":299,"creatinine_mg_dL":0.71,"alt_U_L":28},{"date":"2021-08-26","hemoglobin_g_dL":10.0,"wbc_k_uL":7.8,"platelets_k_uL":194,"creatinine_mg_dL":1.25,"alt_U_L":109},{"date":"2022-07-08","hemoglobin_g_dL":12.9,"wbc_k_uL":4.2,"platelets_k_uL":314,"creatinine_mg_dL":0.83,"alt_U_L":118}]}
|
{"patient_id":"ANODE_SYNTH_2025_027","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.6,"microsatellite_status":"MSS","pd_l1_tps_percent":9},"baseline_clinical":{"age":53,"sex":"female","bmi":23.7,"smoking_pack_years":71,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.6,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-12-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-54},"pfs_months":8.41},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.2,"censored":false},"longitudinal_labs":[{"date":"2024-11-23","hemoglobin_g_dL":13.5,"wbc_k_uL":4.9,"platelets_k_uL":416,"creatinine_mg_dL":0.88,"alt_U_L":78},{"date":"2025-06-14","hemoglobin_g_dL":10.8,"wbc_k_uL":8.8,"platelets_k_uL":297,"creatinine_mg_dL":1.59,"alt_U_L":56},{"date":"2025-10-18","hemoglobin_g_dL":11.1,"wbc_k_uL":4.1,"platelets_k_uL":347,"creatinine_mg_dL":0.83,"alt_U_L":21}]}
|
{"patient_id":"ANODE_SYNTH_2025_028","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":17.7,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":54,"sex":"male","bmi":23.9,"smoking_pack_years":60,"ecog_performance_status":0,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.9,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-12-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-73},"pfs_months":34.2},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":55.0,"censored":false},"longitudinal_labs":[{"date":"2024-10-12","hemoglobin_g_dL":13.8,"wbc_k_uL":4.8,"platelets_k_uL":182,"creatinine_mg_dL":0.6,"alt_U_L":25},{"date":"2025-06-03","hemoglobin_g_dL":10.6,"wbc_k_uL":4.6,"platelets_k_uL":361,"creatinine_mg_dL":1.13,"alt_U_L":74},{"date":"2027-10-31","hemoglobin_g_dL":11.9,"wbc_k_uL":3.5,"platelets_k_uL":183,"creatinine_mg_dL":0.81,"alt_U_L":121}]}
|
{"patient_id":"ANODE_SYNTH_2025_029","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.0,"microsatellite_status":"MSS","pd_l1_tps_percent":2},"baseline_clinical":{"age":65,"sex":"female","bmi":20.8,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["brain","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-50},"pfs_months":23.98},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-12","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.2,"censored":true},"longitudinal_labs":[{"date":"2023-05-21","hemoglobin_g_dL":15.1,"wbc_k_uL":7.1,"platelets_k_uL":222,"creatinine_mg_dL":0.66,"alt_U_L":76},{"date":"2024-01-12","hemoglobin_g_dL":11.8,"wbc_k_uL":8.1,"platelets_k_uL":335,"creatinine_mg_dL":0.96,"alt_U_L":53},{"date":"2025-09-12","hemoglobin_g_dL":10.2,"wbc_k_uL":3.1,"platelets_k_uL":188,"creatinine_mg_dL":1.66,"alt_U_L":179}]}
|
{"patient_id":"ANODE_SYNTH_2025_030","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.3,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":84,"sex":"female","bmi":35.1,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-40},"pfs_months":18.73},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":true},"longitudinal_labs":[{"date":"2023-08-18","hemoglobin_g_dL":12.8,"wbc_k_uL":6.6,"platelets_k_uL":421,"creatinine_mg_dL":1.07,"alt_U_L":45},{"date":"2024-03-30","hemoglobin_g_dL":11.5,"wbc_k_uL":5.2,"platelets_k_uL":238,"creatinine_mg_dL":0.89,"alt_U_L":108},{"date":"2025-06-17","hemoglobin_g_dL":11.8,"wbc_k_uL":5.3,"platelets_k_uL":294,"creatinine_mg_dL":1.39,"alt_U_L":169}]}
|
{"patient_id":"ANODE_SYNTH_2025_031","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":48,"sex":"female","bmi":29.2,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-12-27","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-82},"pfs_months":14.46},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-28","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":30.5,"censored":false},"longitudinal_labs":[{"date":"2023-12-11","hemoglobin_g_dL":12.3,"wbc_k_uL":5.6,"platelets_k_uL":248,"creatinine_mg_dL":0.91,"alt_U_L":42},{"date":"2024-06-24","hemoglobin_g_dL":13.7,"wbc_k_uL":8.6,"platelets_k_uL":314,"creatinine_mg_dL":0.86,"alt_U_L":60},{"date":"2025-04-28","hemoglobin_g_dL":11.3,"wbc_k_uL":3.6,"platelets_k_uL":312,"creatinine_mg_dL":1.49,"alt_U_L":116}]}
|
{"patient_id":"ANODE_SYNTH_2025_032","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":10.3,"microsatellite_status":"MSS","pd_l1_tps_percent":35},"baseline_clinical":{"age":71,"sex":"female","bmi":32.9,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.9,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-02-05","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-42,"peak_response_20wk_change_percent":-33},"pfs_months":13.17},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-27","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":29.4,"censored":false},"longitudinal_labs":[{"date":"2024-12-01","hemoglobin_g_dL":13.2,"wbc_k_uL":9.8,"platelets_k_uL":262,"creatinine_mg_dL":0.69,"alt_U_L":64},{"date":"2025-08-04","hemoglobin_g_dL":11.1,"wbc_k_uL":7.4,"platelets_k_uL":279,"creatinine_mg_dL":1.25,"alt_U_L":102},{"date":"2026-04-27","hemoglobin_g_dL":11.3,"wbc_k_uL":5.5,"platelets_k_uL":254,"creatinine_mg_dL":1.73,"alt_U_L":86}]}
|
{"patient_id":"ANODE_SYNTH_2025_033","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":50,"sex":"male","bmi":37.0,"smoking_pack_years":42,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.5,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2022-03-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-44},"pfs_months":17.81},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-18","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.4,"censored":false},"longitudinal_labs":[{"date":"2022-01-12","hemoglobin_g_dL":13.7,"wbc_k_uL":7.0,"platelets_k_uL":335,"creatinine_mg_dL":0.61,"alt_U_L":54},{"date":"2022-09-16","hemoglobin_g_dL":10.4,"wbc_k_uL":4.0,"platelets_k_uL":184,"creatinine_mg_dL":1.42,"alt_U_L":112},{"date":"2023-10-18","hemoglobin_g_dL":12.3,"wbc_k_uL":4.7,"platelets_k_uL":148,"creatinine_mg_dL":1.44,"alt_U_L":169}]}
|
{"patient_id":"ANODE_SYNTH_2025_034","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.7,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":54,"sex":"male","bmi":20.7,"smoking_pack_years":22,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.4,"metastatic_sites":["liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2025-02-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-35},"pfs_months":5.62},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":18.3,"censored":false},"longitudinal_labs":[{"date":"2024-12-16","hemoglobin_g_dL":13.3,"wbc_k_uL":7.9,"platelets_k_uL":238,"creatinine_mg_dL":0.74,"alt_U_L":36},{"date":"2025-08-12","hemoglobin_g_dL":10.1,"wbc_k_uL":8.5,"platelets_k_uL":235,"creatinine_mg_dL":1.09,"alt_U_L":87},{"date":"2025-08-12","hemoglobin_g_dL":10.3,"wbc_k_uL":4.5,"platelets_k_uL":117,"creatinine_mg_dL":0.87,"alt_U_L":40}]}
|
{"patient_id":"ANODE_SYNTH_2025_035","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":79,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.1,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-04-01","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-33},"pfs_months":24.74},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-06-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":44.6,"censored":false},"longitudinal_labs":[{"date":"2025-01-23","hemoglobin_g_dL":13.2,"wbc_k_uL":9.3,"platelets_k_uL":383,"creatinine_mg_dL":0.94,"alt_U_L":54},{"date":"2025-09-28","hemoglobin_g_dL":12.9,"wbc_k_uL":6.4,"platelets_k_uL":127,"creatinine_mg_dL":0.89,"alt_U_L":77},{"date":"2027-06-22","hemoglobin_g_dL":12.7,"wbc_k_uL":5.0,"platelets_k_uL":298,"creatinine_mg_dL":0.82,"alt_U_L":157}]}
|
{"patient_id":"ANODE_SYNTH_2025_036","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.9,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":51,"sex":"female","bmi":22.4,"smoking_pack_years":21,"ecog_performance_status":2,"comorbidities":["COPD","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-12-30","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-34,"peak_response_20wk_change_percent":-61},"pfs_months":42.28},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":70.4,"censored":false},"longitudinal_labs":[{"date":"2024-12-08","hemoglobin_g_dL":12.9,"wbc_k_uL":6.7,"platelets_k_uL":216,"creatinine_mg_dL":1.2,"alt_U_L":35},{"date":"2025-06-28","hemoglobin_g_dL":13.3,"wbc_k_uL":7.2,"platelets_k_uL":204,"creatinine_mg_dL":1.0,"alt_U_L":90},{"date":"2028-08-13","hemoglobin_g_dL":10.2,"wbc_k_uL":4.7,"platelets_k_uL":255,"creatinine_mg_dL":1.12,"alt_U_L":177}]}
|
{"patient_id":"ANODE_SYNTH_2025_037","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.8,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":72,"sex":"female","bmi":21.6,"smoking_pack_years":68,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-30},"pfs_months":25.92},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-15","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":44.0,"censored":false},"longitudinal_labs":[{"date":"2023-06-25","hemoglobin_g_dL":13.4,"wbc_k_uL":10.5,"platelets_k_uL":418,"creatinine_mg_dL":1.11,"alt_U_L":75},{"date":"2024-01-09","hemoglobin_g_dL":13.8,"wbc_k_uL":7.4,"platelets_k_uL":241,"creatinine_mg_dL":1.32,"alt_U_L":119},{"date":"2025-10-15","hemoglobin_g_dL":11.2,"wbc_k_uL":6.9,"platelets_k_uL":101,"creatinine_mg_dL":1.4,"alt_U_L":113}]}
|
{"patient_id":"ANODE_SYNTH_2025_038","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":65,"sex":"female","bmi":22.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-11-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-80},"pfs_months":19.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-08-24","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.8,"censored":false},"longitudinal_labs":[{"date":"2020-10-05","hemoglobin_g_dL":14.7,"wbc_k_uL":5.3,"platelets_k_uL":396,"creatinine_mg_dL":0.97,"alt_U_L":30},{"date":"2021-05-04","hemoglobin_g_dL":12.0,"wbc_k_uL":7.8,"platelets_k_uL":222,"creatinine_mg_dL":1.04,"alt_U_L":66},{"date":"2022-08-24","hemoglobin_g_dL":11.4,"wbc_k_uL":4.4,"platelets_k_uL":310,"creatinine_mg_dL":1.57,"alt_U_L":105}]}
|
{"patient_id":"ANODE_SYNTH_2025_039","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.6,"microsatellite_status":"MSS","pd_l1_tps_percent":15},"baseline_clinical":{"age":84,"sex":"male","bmi":27.7,"smoking_pack_years":37,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.3,"metastatic_sites":["bone","pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2022-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-36,"peak_response_20wk_change_percent":-63},"pfs_months":15.31},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-10-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-02","hemoglobin_g_dL":13.3,"wbc_k_uL":6.6,"platelets_k_uL":228,"creatinine_mg_dL":1.04,"alt_U_L":12},{"date":"2022-11-29","hemoglobin_g_dL":13.9,"wbc_k_uL":7.3,"platelets_k_uL":130,"creatinine_mg_dL":1.33,"alt_U_L":47},{"date":"2023-10-05","hemoglobin_g_dL":12.5,"wbc_k_uL":4.4,"platelets_k_uL":263,"creatinine_mg_dL":1.08,"alt_U_L":27}]}
|
{"patient_id":"ANODE_SYNTH_2025_040","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":12},"baseline_clinical":{"age":75,"sex":"female","bmi":32.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["brain","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-01-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-45,"peak_response_20wk_change_percent":-75},"pfs_months":17.45},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-08-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":false},"longitudinal_labs":[{"date":"2021-12-27","hemoglobin_g_dL":13.7,"wbc_k_uL":5.6,"platelets_k_uL":216,"creatinine_mg_dL":1.01,"alt_U_L":75},{"date":"2022-07-16","hemoglobin_g_dL":10.5,"wbc_k_uL":4.7,"platelets_k_uL":139,"creatinine_mg_dL":1.13,"alt_U_L":54},{"date":"2023-08-26","hemoglobin_g_dL":10.4,"wbc_k_uL":6.4,"platelets_k_uL":304,"creatinine_mg_dL":1.83,"alt_U_L":188}]}
|
{"patient_id":"ANODE_SYNTH_2025_041","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.9,"microsatellite_status":"MSS","pd_l1_tps_percent":33},"baseline_clinical":{"age":71,"sex":"female","bmi":18.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2025-01-17","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-60},"pfs_months":28.91},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-08-03","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":47.5,"censored":false},"longitudinal_labs":[{"date":"2024-12-25","hemoglobin_g_dL":11.8,"wbc_k_uL":6.8,"platelets_k_uL":402,"creatinine_mg_dL":1.06,"alt_U_L":70},{"date":"2025-07-16","hemoglobin_g_dL":11.2,"wbc_k_uL":6.8,"platelets_k_uL":365,"creatinine_mg_dL":0.78,"alt_U_L":46},{"date":"2027-08-03","hemoglobin_g_dL":11.3,"wbc_k_uL":4.2,"platelets_k_uL":146,"creatinine_mg_dL":1.94,"alt_U_L":65}]}
|
{"patient_id":"ANODE_SYNTH_2025_042","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":58,"sex":"male","bmi":24.9,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["hypertension","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["contralateral lung","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-11-27","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-49,"peak_response_20wk_change_percent":-57},"pfs_months":31.77},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-08-17","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":39.2,"censored":false},"longitudinal_labs":[{"date":"2023-11-02","hemoglobin_g_dL":14.9,"wbc_k_uL":10.3,"platelets_k_uL":162,"creatinine_mg_dL":1.01,"alt_U_L":49},{"date":"2024-05-25","hemoglobin_g_dL":13.3,"wbc_k_uL":4.9,"platelets_k_uL":178,"creatinine_mg_dL":0.91,"alt_U_L":120},{"date":"2026-08-17","hemoglobin_g_dL":12.9,"wbc_k_uL":4.6,"platelets_k_uL":173,"creatinine_mg_dL":0.81,"alt_U_L":149}]}
|
{"patient_id":"ANODE_SYNTH_2025_043","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.6,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":88,"sex":"female","bmi":31.8,"smoking_pack_years":10,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-12-06","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-11,"peak_response_20wk_change_percent":-33},"pfs_months":30.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.1,"censored":false},"longitudinal_labs":[{"date":"2025-11-06","hemoglobin_g_dL":14.5,"wbc_k_uL":7.3,"platelets_k_uL":416,"creatinine_mg_dL":0.81,"alt_U_L":39},{"date":"2026-06-04","hemoglobin_g_dL":13.1,"wbc_k_uL":8.5,"platelets_k_uL":251,"creatinine_mg_dL":1.54,"alt_U_L":93},{"date":"2028-08-01","hemoglobin_g_dL":13.0,"wbc_k_uL":3.9,"platelets_k_uL":264,"creatinine_mg_dL":0.94,"alt_U_L":41}]}
|
{"patient_id":"ANODE_SYNTH_2025_044","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.5,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":56,"sex":"female","bmi":24.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.0,"metastatic_sites":["contralateral lung","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-06-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-47},"pfs_months":23.52},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-07-23","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":32.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-11","hemoglobin_g_dL":11.8,"wbc_k_uL":9.8,"platelets_k_uL":274,"creatinine_mg_dL":0.9,"alt_U_L":35},{"date":"2022-12-09","hemoglobin_g_dL":12.5,"wbc_k_uL":8.3,"platelets_k_uL":307,"creatinine_mg_dL":0.85,"alt_U_L":56},{"date":"2024-07-23","hemoglobin_g_dL":12.0,"wbc_k_uL":6.8,"platelets_k_uL":140,"creatinine_mg_dL":0.84,"alt_U_L":44}]}
|
{"patient_id":"ANODE_SYNTH_2025_045","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.1,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":59,"sex":"female","bmi":21.7,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["bone","liver"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-03-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-82},"pfs_months":25.82},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-30","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":42.3,"censored":false},"longitudinal_labs":[{"date":"2024-02-28","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":210,"creatinine_mg_dL":0.67,"alt_U_L":59},{"date":"2024-09-13","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":262,"creatinine_mg_dL":1.51,"alt_U_L":90},{"date":"2026-05-30","hemoglobin_g_dL":11.1,"wbc_k_uL":4.7,"platelets_k_uL":132,"creatinine_mg_dL":1.75,"alt_U_L":88}]}
|
{"patient_id":"ANODE_SYNTH_2025_046","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":10.6,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":60,"sex":"male","bmi":36.8,"smoking_pack_years":35,"ecog_performance_status":0,"comorbidities":["hypertension","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","brain","contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-03-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-61},"pfs_months":14.65},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2021-05-27","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":22.3,"censored":false},"longitudinal_labs":[{"date":"2020-01-28","hemoglobin_g_dL":11.7,"wbc_k_uL":7.7,"platelets_k_uL":246,"creatinine_mg_dL":0.79,"alt_U_L":22},{"date":"2020-08-30","hemoglobin_g_dL":12.5,"wbc_k_uL":8.2,"platelets_k_uL":137,"creatinine_mg_dL":1.27,"alt_U_L":110},{"date":"2021-05-27","hemoglobin_g_dL":12.1,"wbc_k_uL":7.9,"platelets_k_uL":242,"creatinine_mg_dL":1.15,"alt_U_L":41}]}
|
{"patient_id":"ANODE_SYNTH_2025_047","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"NTRK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":20},"baseline_clinical":{"age":58,"sex":"female","bmi":20.7,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.2,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"larotrectinib 100 mg BID","start_date":"2021-09-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-75},"pfs_months":24.64},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-11-26","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.2,"censored":false},"longitudinal_labs":[{"date":"2021-08-17","hemoglobin_g_dL":14.0,"wbc_k_uL":7.3,"platelets_k_uL":445,"creatinine_mg_dL":1.24,"alt_U_L":66},{"date":"2022-03-18","hemoglobin_g_dL":10.8,"wbc_k_uL":7.5,"platelets_k_uL":216,"creatinine_mg_dL":1.59,"alt_U_L":30},{"date":"2023-11-26","hemoglobin_g_dL":10.7,"wbc_k_uL":6.1,"platelets_k_uL":253,"creatinine_mg_dL":1.91,"alt_U_L":140}]}
|
{"patient_id":"ANODE_SYNTH_2025_048","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.9,"microsatellite_status":"MSS","pd_l1_tps_percent":25},"baseline_clinical":{"age":78,"sex":"female","bmi":24.9,"smoking_pack_years":21,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.0,"metastatic_sites":["contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-31","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-61},"pfs_months":13.9},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":17.8,"censored":false},"longitudinal_labs":[{"date":"2024-03-09","hemoglobin_g_dL":13.2,"wbc_k_uL":10.2,"platelets_k_uL":298,"creatinine_mg_dL":0.92,"alt_U_L":26},{"date":"2024-09-27","hemoglobin_g_dL":10.4,"wbc_k_uL":8.7,"platelets_k_uL":249,"creatinine_mg_dL":1.33,"alt_U_L":69},{"date":"2025-07-04","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":286,"creatinine_mg_dL":1.26,"alt_U_L":38}]}
|
{"patient_id":"ANODE_SYNTH_2025_049","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":2.1,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":66,"sex":"female","bmi":37.8,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-08-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-80},"pfs_months":25.72},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-10-27","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":49.1,"censored":false},"longitudinal_labs":[{"date":"2022-07-11","hemoglobin_g_dL":13.7,"wbc_k_uL":6.4,"platelets_k_uL":295,"creatinine_mg_dL":1.03,"alt_U_L":76},{"date":"2023-02-08","hemoglobin_g_dL":12.5,"wbc_k_uL":5.4,"platelets_k_uL":250,"creatinine_mg_dL":1.02,"alt_U_L":99},{"date":"2024-10-27","hemoglobin_g_dL":11.0,"wbc_k_uL":7.3,"platelets_k_uL":233,"creatinine_mg_dL":1.99,"alt_U_L":80}]}
|
{"patient_id":"ANODE_SYNTH_2025_050","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":4.0,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":60,"sex":"female","bmi":20.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.8,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-37},"pfs_months":24.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":37.4,"censored":true},"longitudinal_labs":[{"date":"2022-04-20","hemoglobin_g_dL":13.7,"wbc_k_uL":7.1,"platelets_k_uL":373,"creatinine_mg_dL":0.9,"alt_U_L":46},{"date":"2022-11-05","hemoglobin_g_dL":13.2,"wbc_k_uL":5.7,"platelets_k_uL":189,"creatinine_mg_dL":1.06,"alt_U_L":49},{"date":"2024-06-13","hemoglobin_g_dL":10.4,"wbc_k_uL":7.3,"platelets_k_uL":216,"creatinine_mg_dL":0.94,"alt_U_L":57}]}
|
{"patient_id":"ANODE_SYNTH_2025_051","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":6.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":66,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.1,"metastatic_sites":["pleura","contralateral lung","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2022-05-03","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-76},"pfs_months":24.41},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-06-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2022-03-28","hemoglobin_g_dL":13.3,"wbc_k_uL":4.8,"platelets_k_uL":182,"creatinine_mg_dL":1.17,"alt_U_L":62},{"date":"2022-10-30","hemoglobin_g_dL":11.3,"wbc_k_uL":6.4,"platelets_k_uL":251,"creatinine_mg_dL":1.22,"alt_U_L":88},{"date":"2024-06-06","hemoglobin_g_dL":11.7,"wbc_k_uL":3.3,"platelets_k_uL":229,"creatinine_mg_dL":1.92,"alt_U_L":160}]}
|
{"patient_id":"ANODE_SYNTH_2025_052","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":6.1,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":51,"sex":"male","bmi":26.7,"smoking_pack_years":52,"ecog_performance_status":1,"comorbidities":["diabetes","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-05-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-21,"peak_response_20wk_change_percent":-56},"pfs_months":41.1},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-11-20","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":60.1,"censored":true},"longitudinal_labs":[{"date":"2023-04-27","hemoglobin_g_dL":14.6,"wbc_k_uL":10.5,"platelets_k_uL":330,"creatinine_mg_dL":0.8,"alt_U_L":31},{"date":"2023-11-10","hemoglobin_g_dL":12.0,"wbc_k_uL":6.6,"platelets_k_uL":292,"creatinine_mg_dL":1.15,"alt_U_L":32},{"date":"2026-11-20","hemoglobin_g_dL":9.8,"wbc_k_uL":4.7,"platelets_k_uL":149,"creatinine_mg_dL":1.38,"alt_U_L":66}]}
|
{"patient_id":"ANODE_SYNTH_2025_053","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.4,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":72,"sex":"female","bmi":24.1,"smoking_pack_years":37,"ecog_performance_status":0,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-01-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-76},"pfs_months":30.92},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":63.9,"censored":false},"longitudinal_labs":[{"date":"2025-01-02","hemoglobin_g_dL":12.6,"wbc_k_uL":5.5,"platelets_k_uL":176,"creatinine_mg_dL":1.18,"alt_U_L":29},{"date":"2025-07-15","hemoglobin_g_dL":10.4,"wbc_k_uL":6.5,"platelets_k_uL":171,"creatinine_mg_dL":1.2,"alt_U_L":120},{"date":"2027-10-04","hemoglobin_g_dL":11.1,"wbc_k_uL":4.9,"platelets_k_uL":191,"creatinine_mg_dL":1.79,"alt_U_L":75}]}
|
{"patient_id":"ANODE_SYNTH_2025_054","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.5,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":87,"sex":"female","bmi":22.2,"smoking_pack_years":61,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.0,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2020-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-51,"peak_response_20wk_change_percent":-64},"pfs_months":20.63},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-17","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":28.3,"censored":true},"longitudinal_labs":[{"date":"2020-05-27","hemoglobin_g_dL":15.0,"wbc_k_uL":6.3,"platelets_k_uL":258,"creatinine_mg_dL":0.96,"alt_U_L":73},{"date":"2021-01-06","hemoglobin_g_dL":11.9,"wbc_k_uL":7.8,"platelets_k_uL":272,"creatinine_mg_dL":0.96,"alt_U_L":116},{"date":"2022-05-17","hemoglobin_g_dL":9.8,"wbc_k_uL":4.0,"platelets_k_uL":333,"creatinine_mg_dL":0.83,"alt_U_L":117}]}
|
{"patient_id":"ANODE_SYNTH_2025_055","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":83,"sex":"female","bmi":36.8,"smoking_pack_years":53,"ecog_performance_status":2,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.2,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-04-23","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-29,"peak_response_20wk_change_percent":-30},"pfs_months":27.86},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-09-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":44.1,"censored":false},"longitudinal_labs":[{"date":"2022-04-09","hemoglobin_g_dL":13.2,"wbc_k_uL":7.2,"platelets_k_uL":396,"creatinine_mg_dL":0.89,"alt_U_L":50},{"date":"2022-10-20","hemoglobin_g_dL":11.1,"wbc_k_uL":7.5,"platelets_k_uL":251,"creatinine_mg_dL":1.06,"alt_U_L":41},{"date":"2024-09-04","hemoglobin_g_dL":12.6,"wbc_k_uL":5.2,"platelets_k_uL":317,"creatinine_mg_dL":1.39,"alt_U_L":57}]}
|
{"patient_id":"ANODE_SYNTH_2025_056","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.9,"microsatellite_status":"MSS","pd_l1_tps_percent":4},"baseline_clinical":{"age":71,"sex":"female","bmi":34.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.4,"metastatic_sites":["liver","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2026-03-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-22,"peak_response_20wk_change_percent":-80},"pfs_months":23.46},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-04-05","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":32.9,"censored":false},"longitudinal_labs":[{"date":"2025-12-22","hemoglobin_g_dL":15.4,"wbc_k_uL":8.2,"platelets_k_uL":161,"creatinine_mg_dL":1.07,"alt_U_L":58},{"date":"2026-08-29","hemoglobin_g_dL":12.5,"wbc_k_uL":7.6,"platelets_k_uL":316,"creatinine_mg_dL":1.4,"alt_U_L":54},{"date":"2028-04-05","hemoglobin_g_dL":11.1,"wbc_k_uL":4.5,"platelets_k_uL":280,"creatinine_mg_dL":1.79,"alt_U_L":104}]}
|
{"patient_id":"ANODE_SYNTH_2025_057","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.8,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":66,"sex":"male","bmi":36.1,"smoking_pack_years":30,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-66},"pfs_months":35.88},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-10","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":64.5,"censored":false},"longitudinal_labs":[{"date":"2023-02-04","hemoglobin_g_dL":11.9,"wbc_k_uL":8.9,"platelets_k_uL":347,"creatinine_mg_dL":1.15,"alt_U_L":18},{"date":"2023-08-19","hemoglobin_g_dL":11.8,"wbc_k_uL":7.5,"platelets_k_uL":192,"creatinine_mg_dL":0.8,"alt_U_L":45},{"date":"2026-04-10","hemoglobin_g_dL":12.6,"wbc_k_uL":3.3,"platelets_k_uL":195,"creatinine_mg_dL":0.91,"alt_U_L":64}]}
|
{"patient_id":"ANODE_SYNTH_2025_058","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.1,"microsatellite_status":"MSS","pd_l1_tps_percent":28},"baseline_clinical":{"age":73,"sex":"male","bmi":25.3,"smoking_pack_years":29,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-09","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-77},"pfs_months":4.57},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":11.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-27","hemoglobin_g_dL":15.5,"wbc_k_uL":9.8,"platelets_k_uL":189,"creatinine_mg_dL":1.23,"alt_U_L":53},{"date":"2026-07-08","hemoglobin_g_dL":12.6,"wbc_k_uL":8.2,"platelets_k_uL":365,"creatinine_mg_dL":0.75,"alt_U_L":83},{"date":"2026-06-18","hemoglobin_g_dL":12.4,"wbc_k_uL":4.6,"platelets_k_uL":301,"creatinine_mg_dL":1.22,"alt_U_L":179}]}
|
{"patient_id":"ANODE_SYNTH_2025_059","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.7,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":57,"sex":"male","bmi":30.1,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.3,"metastatic_sites":["pleura"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2021-07-06","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-63},"pfs_months":7.69},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-04-12","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.0,"censored":false},"longitudinal_labs":[{"date":"2021-06-17","hemoglobin_g_dL":13.9,"wbc_k_uL":8.5,"platelets_k_uL":276,"creatinine_mg_dL":1.05,"alt_U_L":64},{"date":"2022-01-02","hemoglobin_g_dL":12.4,"wbc_k_uL":6.9,"platelets_k_uL":192,"creatinine_mg_dL":0.76,"alt_U_L":43},{"date":"2022-04-12","hemoglobin_g_dL":10.1,"wbc_k_uL":7.9,"platelets_k_uL":141,"creatinine_mg_dL":1.25,"alt_U_L":138}]}
|
{"patient_id":"ANODE_SYNTH_2025_060","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.2,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":63,"sex":"female","bmi":20.7,"smoking_pack_years":73,"ecog_performance_status":1,"comorbidities":["hypertension","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.4,"metastatic_sites":["brain","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2026-01-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-84},"pfs_months":7.43},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-13","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":27.9,"censored":false},"longitudinal_labs":[{"date":"2025-11-11","hemoglobin_g_dL":11.6,"wbc_k_uL":8.0,"platelets_k_uL":302,"creatinine_mg_dL":1.1,"alt_U_L":43},{"date":"2026-07-01","hemoglobin_g_dL":11.2,"wbc_k_uL":8.4,"platelets_k_uL":324,"creatinine_mg_dL":1.1,"alt_U_L":76},{"date":"2026-10-13","hemoglobin_g_dL":11.1,"wbc_k_uL":3.3,"platelets_k_uL":152,"creatinine_mg_dL":1.08,"alt_U_L":108}]}
|
{"patient_id":"ANODE_SYNTH_2025_061","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":53,"sex":"female","bmi":23.5,"smoking_pack_years":75,"ecog_performance_status":0,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-02-14","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-54,"peak_response_20wk_change_percent":-56},"pfs_months":13.6},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2022-05-16","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":27.8,"censored":false},"longitudinal_labs":[{"date":"2021-01-25","hemoglobin_g_dL":14.5,"wbc_k_uL":10.8,"platelets_k_uL":318,"creatinine_mg_dL":0.98,"alt_U_L":76},{"date":"2021-08-13","hemoglobin_g_dL":10.4,"wbc_k_uL":5.3,"platelets_k_uL":139,"creatinine_mg_dL":1.54,"alt_U_L":85},{"date":"2022-05-16","hemoglobin_g_dL":10.1,"wbc_k_uL":3.2,"platelets_k_uL":157,"creatinine_mg_dL":1.11,"alt_U_L":40}]}
|
{"patient_id":"ANODE_SYNTH_2025_062","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.4,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":67,"sex":"female","bmi":23.9,"smoking_pack_years":78,"ecog_performance_status":1,"comorbidities":["diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["bone","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-04-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-33},"pfs_months":37.16},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-06-05","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":61.3,"censored":false},"longitudinal_labs":[{"date":"2025-03-18","hemoglobin_g_dL":14.1,"wbc_k_uL":5.9,"platelets_k_uL":235,"creatinine_mg_dL":0.71,"alt_U_L":31},{"date":"2025-10-01","hemoglobin_g_dL":11.4,"wbc_k_uL":4.2,"platelets_k_uL":356,"creatinine_mg_dL":0.89,"alt_U_L":16},{"date":"2028-06-05","hemoglobin_g_dL":12.4,"wbc_k_uL":7.9,"platelets_k_uL":346,"creatinine_mg_dL":1.67,"alt_U_L":127}]}
|
{"patient_id":"ANODE_SYNTH_2025_063","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.9,"microsatellite_status":"MSS","pd_l1_tps_percent":18},"baseline_clinical":{"age":69,"sex":"male","bmi":32.8,"smoking_pack_years":46,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["contralateral lung","pleura","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-06-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-35,"peak_response_20wk_change_percent":-67},"pfs_months":26.12},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-09-22","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":59.0,"censored":false},"longitudinal_labs":[{"date":"2023-04-14","hemoglobin_g_dL":14.6,"wbc_k_uL":6.2,"platelets_k_uL":387,"creatinine_mg_dL":1.1,"alt_U_L":80},{"date":"2023-12-08","hemoglobin_g_dL":11.5,"wbc_k_uL":5.7,"platelets_k_uL":264,"creatinine_mg_dL":1.31,"alt_U_L":26},{"date":"2025-09-22","hemoglobin_g_dL":12.5,"wbc_k_uL":7.8,"platelets_k_uL":350,"creatinine_mg_dL":1.51,"alt_U_L":125}]}
|
{"patient_id":"ANODE_SYNTH_2025_064","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":49,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["bone","liver","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-05-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-30,"peak_response_20wk_change_percent":-53},"pfs_months":15.9},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":23.8,"censored":true},"longitudinal_labs":[{"date":"2024-04-18","hemoglobin_g_dL":14.1,"wbc_k_uL":9.7,"platelets_k_uL":381,"creatinine_mg_dL":1.22,"alt_U_L":47},{"date":"2024-11-12","hemoglobin_g_dL":12.8,"wbc_k_uL":5.4,"platelets_k_uL":135,"creatinine_mg_dL":1.59,"alt_U_L":101},{"date":"2025-10-26","hemoglobin_g_dL":9.6,"wbc_k_uL":7.7,"platelets_k_uL":279,"creatinine_mg_dL":1.41,"alt_U_L":67}]}
|
{"patient_id":"ANODE_SYNTH_2025_065","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.0,"microsatellite_status":"MSS","pd_l1_tps_percent":1},"baseline_clinical":{"age":55,"sex":"female","bmi":25.7,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.9,"metastatic_sites":["bone","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2020-07-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-41,"peak_response_20wk_change_percent":-85},"pfs_months":28.39},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-01-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":39.0,"censored":true},"longitudinal_labs":[{"date":"2020-05-09","hemoglobin_g_dL":12.4,"wbc_k_uL":8.5,"platelets_k_uL":361,"creatinine_mg_dL":1.06,"alt_U_L":50},{"date":"2021-01-09","hemoglobin_g_dL":10.2,"wbc_k_uL":7.2,"platelets_k_uL":231,"creatinine_mg_dL":1.24,"alt_U_L":37},{"date":"2023-01-18","hemoglobin_g_dL":12.2,"wbc_k_uL":7.2,"platelets_k_uL":261,"creatinine_mg_dL":1.03,"alt_U_L":63}]}
|
{"patient_id":"ANODE_SYNTH_2025_066","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":16.4,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":84,"sex":"female","bmi":24.0,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.3,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-09-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-14,"peak_response_20wk_change_percent":-68},"pfs_months":31.51},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-05-13","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":36.6,"censored":false},"longitudinal_labs":[{"date":"2024-08-11","hemoglobin_g_dL":14.3,"wbc_k_uL":6.6,"platelets_k_uL":389,"creatinine_mg_dL":0.96,"alt_U_L":42},{"date":"2025-03-03","hemoglobin_g_dL":11.9,"wbc_k_uL":3.8,"platelets_k_uL":233,"creatinine_mg_dL":0.91,"alt_U_L":81},{"date":"2027-05-13","hemoglobin_g_dL":11.7,"wbc_k_uL":6.9,"platelets_k_uL":261,"creatinine_mg_dL":1.34,"alt_U_L":73}]}
|
{"patient_id":"ANODE_SYNTH_2025_067","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.6,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":51,"sex":"female","bmi":20.6,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["pleura","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-07-09","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-56,"peak_response_20wk_change_percent":-53},"pfs_months":22.83},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-07-14","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":37.3,"censored":false},"longitudinal_labs":[{"date":"2021-06-04","hemoglobin_g_dL":13.9,"wbc_k_uL":7.5,"platelets_k_uL":373,"creatinine_mg_dL":0.86,"alt_U_L":36},{"date":"2022-01-05","hemoglobin_g_dL":11.5,"wbc_k_uL":7.7,"platelets_k_uL":224,"creatinine_mg_dL":1.2,"alt_U_L":78},{"date":"2023-07-14","hemoglobin_g_dL":12.2,"wbc_k_uL":7.9,"platelets_k_uL":237,"creatinine_mg_dL":1.63,"alt_U_L":53}]}
|
{"patient_id":"ANODE_SYNTH_2025_068","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.3,"microsatellite_status":"MSS","pd_l1_tps_percent":27},"baseline_clinical":{"age":55,"sex":"female","bmi":35.4,"smoking_pack_years":54,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.8,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-05-11","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-13,"peak_response_20wk_change_percent":-38},"pfs_months":37.49},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2028-07-18","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":62.7,"censored":false},"longitudinal_labs":[{"date":"2025-04-18","hemoglobin_g_dL":11.9,"wbc_k_uL":7.6,"platelets_k_uL":387,"creatinine_mg_dL":1.15,"alt_U_L":21},{"date":"2025-11-07","hemoglobin_g_dL":12.4,"wbc_k_uL":7.3,"platelets_k_uL":315,"creatinine_mg_dL":0.96,"alt_U_L":27},{"date":"2028-07-18","hemoglobin_g_dL":12.3,"wbc_k_uL":4.4,"platelets_k_uL":297,"creatinine_mg_dL":1.67,"alt_U_L":172}]}
|
{"patient_id":"ANODE_SYNTH_2025_069","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.3,"microsatellite_status":"MSS","pd_l1_tps_percent":19},"baseline_clinical":{"age":80,"sex":"female","bmi":18.9,"smoking_pack_years":54,"ecog_performance_status":0,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.2,"metastatic_sites":["pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-04-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-23,"peak_response_20wk_change_percent":-74},"pfs_months":39.33},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-10-02","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.1,"censored":false},"longitudinal_labs":[{"date":"2023-03-04","hemoglobin_g_dL":12.5,"wbc_k_uL":6.1,"platelets_k_uL":362,"creatinine_mg_dL":1.05,"alt_U_L":72},{"date":"2023-10-23","hemoglobin_g_dL":10.5,"wbc_k_uL":6.0,"platelets_k_uL":380,"creatinine_mg_dL":1.59,"alt_U_L":56},{"date":"2026-10-02","hemoglobin_g_dL":9.8,"wbc_k_uL":5.5,"platelets_k_uL":147,"creatinine_mg_dL":1.21,"alt_U_L":97}]}
|
{"patient_id":"ANODE_SYNTH_2025_070","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":67,"sex":"female","bmi":30.8,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2024-08-15","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-47,"peak_response_20wk_change_percent":-33},"pfs_months":37.26},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-15","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":66.1,"censored":false},"longitudinal_labs":[{"date":"2024-07-20","hemoglobin_g_dL":13.4,"wbc_k_uL":5.5,"platelets_k_uL":383,"creatinine_mg_dL":1.0,"alt_U_L":27},{"date":"2025-02-11","hemoglobin_g_dL":10.6,"wbc_k_uL":4.1,"platelets_k_uL":324,"creatinine_mg_dL":1.41,"alt_U_L":76},{"date":"2027-10-15","hemoglobin_g_dL":11.3,"wbc_k_uL":6.3,"platelets_k_uL":127,"creatinine_mg_dL":2.0,"alt_U_L":37}]}
|
{"patient_id":"ANODE_SYNTH_2025_071","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":80,"sex":"female","bmi":22.7,"smoking_pack_years":0,"ecog_performance_status":0,"comorbidities":["hyperlipidemia","diabetes"]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.8,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2021-12-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-44},"pfs_months":19.09},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-09-23","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":40.1,"censored":true},"longitudinal_labs":[{"date":"2021-11-17","hemoglobin_g_dL":13.3,"wbc_k_uL":8.7,"platelets_k_uL":377,"creatinine_mg_dL":0.99,"alt_U_L":75},{"date":"2022-06-23","hemoglobin_g_dL":13.6,"wbc_k_uL":8.1,"platelets_k_uL":263,"creatinine_mg_dL":0.8,"alt_U_L":34},{"date":"2023-09-23","hemoglobin_g_dL":11.0,"wbc_k_uL":7.5,"platelets_k_uL":181,"creatinine_mg_dL":0.91,"alt_U_L":159}]}
|
{"patient_id":"ANODE_SYNTH_2025_072","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":76,"sex":"female","bmi":19.7,"smoking_pack_years":55,"ecog_performance_status":0,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.7,"metastatic_sites":["contralateral lung","pleura","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-05-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-47},"pfs_months":21.16},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":43.4,"censored":true},"longitudinal_labs":[{"date":"2023-03-19","hemoglobin_g_dL":13.9,"wbc_k_uL":10.9,"platelets_k_uL":162,"creatinine_mg_dL":1.22,"alt_U_L":42},{"date":"2023-10-29","hemoglobin_g_dL":10.1,"wbc_k_uL":6.4,"platelets_k_uL":356,"creatinine_mg_dL":0.88,"alt_U_L":53},{"date":"2025-03-31","hemoglobin_g_dL":12.3,"wbc_k_uL":3.5,"platelets_k_uL":125,"creatinine_mg_dL":1.48,"alt_U_L":25}]}
|
{"patient_id":"ANODE_SYNTH_2025_073","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.5,"microsatellite_status":"MSS","pd_l1_tps_percent":30},"baseline_clinical":{"age":60,"sex":"female","bmi":31.6,"smoking_pack_years":45,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.6,"metastatic_sites":["liver","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-05-26","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-81},"pfs_months":35.25},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-06-01","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":62.8,"censored":false},"longitudinal_labs":[{"date":"2022-03-27","hemoglobin_g_dL":12.3,"wbc_k_uL":8.8,"platelets_k_uL":256,"creatinine_mg_dL":1.18,"alt_U_L":55},{"date":"2022-11-22","hemoglobin_g_dL":10.6,"wbc_k_uL":6.5,"platelets_k_uL":293,"creatinine_mg_dL":1.02,"alt_U_L":62},{"date":"2025-06-01","hemoglobin_g_dL":10.3,"wbc_k_uL":5.4,"platelets_k_uL":310,"creatinine_mg_dL":1.86,"alt_U_L":86}]}
|
{"patient_id":"ANODE_SYNTH_2025_074","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.2,"microsatellite_status":"MSS","pd_l1_tps_percent":3},"baseline_clinical":{"age":79,"sex":"male","bmi":28.5,"smoking_pack_years":32,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2024-03-19","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-60,"peak_response_20wk_change_percent":-76},"pfs_months":11.33},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-11","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":20.5,"censored":false},"longitudinal_labs":[{"date":"2024-01-14","hemoglobin_g_dL":11.6,"wbc_k_uL":6.3,"platelets_k_uL":189,"creatinine_mg_dL":1.08,"alt_U_L":37},{"date":"2024-09-15","hemoglobin_g_dL":11.9,"wbc_k_uL":9.0,"platelets_k_uL":233,"creatinine_mg_dL":0.85,"alt_U_L":79},{"date":"2025-04-11","hemoglobin_g_dL":11.4,"wbc_k_uL":3.7,"platelets_k_uL":264,"creatinine_mg_dL":1.27,"alt_U_L":86}]}
|
{"patient_id":"ANODE_SYNTH_2025_075","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":78,"sex":"female","bmi":35.6,"smoking_pack_years":47,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.0,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-06-04","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-27,"peak_response_20wk_change_percent":-38},"pfs_months":19.38},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-03-11","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":29.5,"censored":false},"longitudinal_labs":[{"date":"2021-05-15","hemoglobin_g_dL":12.7,"wbc_k_uL":10.8,"platelets_k_uL":332,"creatinine_mg_dL":1.18,"alt_U_L":11},{"date":"2021-12-01","hemoglobin_g_dL":11.4,"wbc_k_uL":6.0,"platelets_k_uL":225,"creatinine_mg_dL":1.24,"alt_U_L":106},{"date":"2023-03-11","hemoglobin_g_dL":11.6,"wbc_k_uL":5.3,"platelets_k_uL":247,"creatinine_mg_dL":1.3,"alt_U_L":88}]}
|
{"patient_id":"ANODE_SYNTH_2025_076","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":15.3,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":78,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-10-25","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-44},"pfs_months":20.4},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-07-12","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":33.1,"censored":false},"longitudinal_labs":[{"date":"2024-09-21","hemoglobin_g_dL":14.4,"wbc_k_uL":4.6,"platelets_k_uL":321,"creatinine_mg_dL":0.63,"alt_U_L":61},{"date":"2025-04-23","hemoglobin_g_dL":12.2,"wbc_k_uL":8.8,"platelets_k_uL":343,"creatinine_mg_dL":0.92,"alt_U_L":67},{"date":"2026-07-12","hemoglobin_g_dL":10.5,"wbc_k_uL":3.4,"platelets_k_uL":314,"creatinine_mg_dL":1.43,"alt_U_L":49}]}
|
{"patient_id":"ANODE_SYNTH_2025_077","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.0,"microsatellite_status":"MSS","pd_l1_tps_percent":31},"baseline_clinical":{"age":55,"sex":"female","bmi":23.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.1,"metastatic_sites":["contralateral lung","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-10,"peak_response_20wk_change_percent":-54},"pfs_months":29.44},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-04","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":true},"longitudinal_labs":[{"date":"2023-08-26","hemoglobin_g_dL":13.0,"wbc_k_uL":7.6,"platelets_k_uL":409,"creatinine_mg_dL":0.69,"alt_U_L":44},{"date":"2024-04-15","hemoglobin_g_dL":12.5,"wbc_k_uL":5.4,"platelets_k_uL":283,"creatinine_mg_dL":1.38,"alt_U_L":16},{"date":"2026-05-04","hemoglobin_g_dL":10.5,"wbc_k_uL":6.9,"platelets_k_uL":265,"creatinine_mg_dL":1.84,"alt_U_L":101}]}
|
{"patient_id":"ANODE_SYNTH_2025_078","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":8.6,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":60,"sex":"female","bmi":25.4,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["diabetes","hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-11-29","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-31,"peak_response_20wk_change_percent":-56},"pfs_months":19.84},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":36.7,"censored":false},"longitudinal_labs":[{"date":"2023-11-05","hemoglobin_g_dL":12.9,"wbc_k_uL":8.6,"platelets_k_uL":393,"creatinine_mg_dL":0.71,"alt_U_L":45},{"date":"2024-05-27","hemoglobin_g_dL":13.0,"wbc_k_uL":4.6,"platelets_k_uL":313,"creatinine_mg_dL":1.26,"alt_U_L":60},{"date":"2025-08-25","hemoglobin_g_dL":10.0,"wbc_k_uL":4.5,"platelets_k_uL":216,"creatinine_mg_dL":1.83,"alt_U_L":148}]}
|
{"patient_id":"ANODE_SYNTH_2025_079","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":3.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"male","bmi":29.7,"smoking_pack_years":65,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["bone","liver","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2023-02-12","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-24,"peak_response_20wk_change_percent":-46},"pfs_months":36.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-03-07","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":67.0,"censored":false},"longitudinal_labs":[{"date":"2022-12-22","hemoglobin_g_dL":12.0,"wbc_k_uL":7.2,"platelets_k_uL":335,"creatinine_mg_dL":0.79,"alt_U_L":14},{"date":"2023-08-11","hemoglobin_g_dL":11.0,"wbc_k_uL":4.3,"platelets_k_uL":166,"creatinine_mg_dL":1.06,"alt_U_L":29},{"date":"2026-03-07","hemoglobin_g_dL":10.0,"wbc_k_uL":7.7,"platelets_k_uL":334,"creatinine_mg_dL":1.92,"alt_U_L":175}]}
|
{"patient_id":"ANODE_SYNTH_2025_080","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":8.1,"microsatellite_status":"MSS","pd_l1_tps_percent":29},"baseline_clinical":{"age":87,"sex":"male","bmi":27.6,"smoking_pack_years":12,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-03-24","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-41},"pfs_months":30.78},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-11-23","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":50.0,"censored":true},"longitudinal_labs":[{"date":"2025-02-10","hemoglobin_g_dL":13.2,"wbc_k_uL":10.8,"platelets_k_uL":278,"creatinine_mg_dL":0.66,"alt_U_L":18},{"date":"2025-09-20","hemoglobin_g_dL":13.6,"wbc_k_uL":4.3,"platelets_k_uL":189,"creatinine_mg_dL":1.23,"alt_U_L":83},{"date":"2027-11-23","hemoglobin_g_dL":12.1,"wbc_k_uL":3.2,"platelets_k_uL":178,"creatinine_mg_dL":1.3,"alt_U_L":29}]}
|
{"patient_id":"ANODE_SYNTH_2025_081","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.8,"microsatellite_status":"MSS","pd_l1_tps_percent":13},"baseline_clinical":{"age":65,"sex":"female","bmi":20.3,"smoking_pack_years":68,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.9,"metastatic_sites":["brain","contralateral lung","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-07-12","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-18,"peak_response_20wk_change_percent":-80},"pfs_months":36.44},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-07","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":56.3,"censored":false},"longitudinal_labs":[{"date":"2022-05-08","hemoglobin_g_dL":11.9,"wbc_k_uL":8.4,"platelets_k_uL":216,"creatinine_mg_dL":1.13,"alt_U_L":51},{"date":"2023-01-08","hemoglobin_g_dL":13.3,"wbc_k_uL":4.2,"platelets_k_uL":209,"creatinine_mg_dL":1.47,"alt_U_L":46},{"date":"2025-08-07","hemoglobin_g_dL":11.1,"wbc_k_uL":6.8,"platelets_k_uL":233,"creatinine_mg_dL":1.28,"alt_U_L":126}]}
|
{"patient_id":"ANODE_SYNTH_2025_082","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.7,"microsatellite_status":"MSS","pd_l1_tps_percent":11},"baseline_clinical":{"age":57,"sex":"male","bmi":34.7,"smoking_pack_years":69,"ecog_performance_status":1,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2021-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-38,"peak_response_20wk_change_percent":-41},"pfs_months":18.79},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-05-06","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":30.7,"censored":false},"longitudinal_labs":[{"date":"2021-07-02","hemoglobin_g_dL":12.4,"wbc_k_uL":5.2,"platelets_k_uL":340,"creatinine_mg_dL":1.01,"alt_U_L":37},{"date":"2022-02-14","hemoglobin_g_dL":10.9,"wbc_k_uL":8.0,"platelets_k_uL":170,"creatinine_mg_dL":1.11,"alt_U_L":56},{"date":"2023-05-06","hemoglobin_g_dL":10.5,"wbc_k_uL":7.7,"platelets_k_uL":107,"creatinine_mg_dL":1.36,"alt_U_L":162}]}
|
{"patient_id":"ANODE_SYNTH_2025_083","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":2.6,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":83,"sex":"female","bmi":24.3,"smoking_pack_years":65,"ecog_performance_status":2,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.2,"metastatic_sites":["pleura","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2025-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-33,"peak_response_20wk_change_percent":-83},"pfs_months":43.17},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2029-06-13","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":59.4,"censored":false},"longitudinal_labs":[{"date":"2025-09-20","hemoglobin_g_dL":12.2,"wbc_k_uL":5.7,"platelets_k_uL":388,"creatinine_mg_dL":1.16,"alt_U_L":71},{"date":"2026-04-11","hemoglobin_g_dL":11.0,"wbc_k_uL":6.2,"platelets_k_uL":244,"creatinine_mg_dL":1.55,"alt_U_L":50},{"date":"2029-06-13","hemoglobin_g_dL":9.5,"wbc_k_uL":3.8,"platelets_k_uL":162,"creatinine_mg_dL":1.19,"alt_U_L":115}]}
|
{"patient_id":"ANODE_SYNTH_2025_084","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.2,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":68,"sex":"male","bmi":19.3,"smoking_pack_years":25,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2021-03-08","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-53,"peak_response_20wk_change_percent":-51},"pfs_months":35.22},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-03-02","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":61.2,"censored":false},"longitudinal_labs":[{"date":"2020-12-28","hemoglobin_g_dL":14.7,"wbc_k_uL":10.3,"platelets_k_uL":245,"creatinine_mg_dL":1.05,"alt_U_L":40},{"date":"2021-09-04","hemoglobin_g_dL":12.2,"wbc_k_uL":7.9,"platelets_k_uL":278,"creatinine_mg_dL":0.9,"alt_U_L":69},{"date":"2024-03-02","hemoglobin_g_dL":9.8,"wbc_k_uL":3.8,"platelets_k_uL":261,"creatinine_mg_dL":0.81,"alt_U_L":109}]}
|
{"patient_id":"ANODE_SYNTH_2025_085","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR exon 19 deletion","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":22},"baseline_clinical":{"age":62,"sex":"female","bmi":28.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["diabetes","hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.5,"metastatic_sites":["brain","liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-16","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-32,"peak_response_20wk_change_percent":-47},"pfs_months":26.48},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-07-01","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":35.8,"censored":false},"longitudinal_labs":[{"date":"2023-02-08","hemoglobin_g_dL":13.0,"wbc_k_uL":8.9,"platelets_k_uL":162,"creatinine_mg_dL":0.65,"alt_U_L":25},{"date":"2023-09-12","hemoglobin_g_dL":11.2,"wbc_k_uL":5.4,"platelets_k_uL":277,"creatinine_mg_dL":0.83,"alt_U_L":89},{"date":"2025-07-01","hemoglobin_g_dL":10.7,"wbc_k_uL":3.1,"platelets_k_uL":138,"creatinine_mg_dL":1.82,"alt_U_L":186}]}
|
{"patient_id":"ANODE_SYNTH_2025_086","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":84,"sex":"male","bmi":21.8,"smoking_pack_years":40,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":8.4,"metastatic_sites":["pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2023-06-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-17,"peak_response_20wk_change_percent":-52},"pfs_months":21.55},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-03-31","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":27.7,"censored":false},"longitudinal_labs":[{"date":"2023-05-08","hemoglobin_g_dL":12.3,"wbc_k_uL":8.6,"platelets_k_uL":402,"creatinine_mg_dL":0.66,"alt_U_L":65},{"date":"2023-11-29","hemoglobin_g_dL":12.7,"wbc_k_uL":4.9,"platelets_k_uL":334,"creatinine_mg_dL":0.85,"alt_U_L":105},{"date":"2025-03-31","hemoglobin_g_dL":12.3,"wbc_k_uL":7.6,"platelets_k_uL":123,"creatinine_mg_dL":1.81,"alt_U_L":28}]}
|
{"patient_id":"ANODE_SYNTH_2025_087","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":4.2,"microsatellite_status":"MSS","pd_l1_tps_percent":8},"baseline_clinical":{"age":66,"sex":"female","bmi":25.3,"smoking_pack_years":19,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","brain"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-02","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-52,"peak_response_20wk_change_percent":-46},"pfs_months":31.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-08-01","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":58.9,"censored":false},"longitudinal_labs":[{"date":"2022-10-26","hemoglobin_g_dL":11.5,"wbc_k_uL":6.5,"platelets_k_uL":361,"creatinine_mg_dL":1.09,"alt_U_L":35},{"date":"2023-05-31","hemoglobin_g_dL":13.2,"wbc_k_uL":7.8,"platelets_k_uL":332,"creatinine_mg_dL":0.96,"alt_U_L":65},{"date":"2025-08-01","hemoglobin_g_dL":12.0,"wbc_k_uL":5.0,"platelets_k_uL":192,"creatinine_mg_dL":1.97,"alt_U_L":65}]}
|
{"patient_id":"ANODE_SYNTH_2025_088","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":5.2,"microsatellite_status":"MSS","pd_l1_tps_percent":32},"baseline_clinical":{"age":67,"sex":"female","bmi":18.9,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":["COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.6,"metastatic_sites":["brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-01-03","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-44,"peak_response_20wk_change_percent":-33},"pfs_months":28.88},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-18","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":41.1,"censored":true},"longitudinal_labs":[{"date":"2023-12-01","hemoglobin_g_dL":12.5,"wbc_k_uL":6.7,"platelets_k_uL":328,"creatinine_mg_dL":0.79,"alt_U_L":53},{"date":"2024-07-01","hemoglobin_g_dL":12.3,"wbc_k_uL":6.7,"platelets_k_uL":300,"creatinine_mg_dL":0.87,"alt_U_L":43},{"date":"2026-06-18","hemoglobin_g_dL":11.7,"wbc_k_uL":6.9,"platelets_k_uL":305,"creatinine_mg_dL":1.19,"alt_U_L":63}]}
|
{"patient_id":"ANODE_SYNTH_2025_089","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.1,"microsatellite_status":"MSS","pd_l1_tps_percent":24},"baseline_clinical":{"age":62,"sex":"male","bmi":30.8,"smoking_pack_years":62,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.6,"metastatic_sites":["bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2023-09-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-82},"pfs_months":17.38},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-24","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","none"]}},"survival_outcomes":{"overall_survival_months":25.6,"censored":false},"longitudinal_labs":[{"date":"2023-07-07","hemoglobin_g_dL":13.3,"wbc_k_uL":7.1,"platelets_k_uL":403,"creatinine_mg_dL":0.78,"alt_U_L":16},{"date":"2024-03-13","hemoglobin_g_dL":12.1,"wbc_k_uL":4.5,"platelets_k_uL":232,"creatinine_mg_dL":1.23,"alt_U_L":25},{"date":"2025-04-24","hemoglobin_g_dL":12.4,"wbc_k_uL":4.1,"platelets_k_uL":159,"creatinine_mg_dL":1.04,"alt_U_L":31}]}
|
{"patient_id":"ANODE_SYNTH_2025_090","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":15.5,"microsatellite_status":"MSS","pd_l1_tps_percent":16},"baseline_clinical":{"age":62,"sex":"female","bmi":29.8,"smoking_pack_years":68,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.6,"metastatic_sites":["brain","liver","contralateral lung"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-10-17","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-15,"peak_response_20wk_change_percent":-64},"pfs_months":36.86},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2024-01-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":60.8,"censored":false},"longitudinal_labs":[{"date":"2020-09-12","hemoglobin_g_dL":12.8,"wbc_k_uL":9.1,"platelets_k_uL":241,"creatinine_mg_dL":1.04,"alt_U_L":66},{"date":"2021-04-15","hemoglobin_g_dL":10.1,"wbc_k_uL":4.9,"platelets_k_uL":345,"creatinine_mg_dL":1.46,"alt_U_L":92},{"date":"2024-01-06","hemoglobin_g_dL":10.8,"wbc_k_uL":6.9,"platelets_k_uL":261,"creatinine_mg_dL":1.32,"alt_U_L":113}]}
|
{"patient_id":"ANODE_SYNTH_2025_091","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.2,"microsatellite_status":"MSS","pd_l1_tps_percent":26},"baseline_clinical":{"age":58,"sex":"male","bmi":30.9,"smoking_pack_years":31,"ecog_performance_status":0,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.5,"metastatic_sites":["contralateral lung"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-40,"peak_response_20wk_change_percent":-35},"pfs_months":2.96},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-20","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":12.1,"censored":false},"longitudinal_labs":[{"date":"2025-05-11","hemoglobin_g_dL":12.0,"wbc_k_uL":4.5,"platelets_k_uL":196,"creatinine_mg_dL":1.21,"alt_U_L":22},{"date":"2025-12-15","hemoglobin_g_dL":10.1,"wbc_k_uL":5.2,"platelets_k_uL":292,"creatinine_mg_dL":1.09,"alt_U_L":69},{"date":"2025-10-20","hemoglobin_g_dL":10.7,"wbc_k_uL":5.4,"platelets_k_uL":261,"creatinine_mg_dL":1.03,"alt_U_L":20}]}
|
{"patient_id":"ANODE_SYNTH_2025_092","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":11.8,"microsatellite_status":"MSS","pd_l1_tps_percent":0},"baseline_clinical":{"age":48,"sex":"female","bmi":29.3,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.0,"metastatic_sites":["brain","bone","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2024-02-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-25,"peak_response_20wk_change_percent":-81},"pfs_months":12.19},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-04-10","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":34.3,"censored":false},"longitudinal_labs":[{"date":"2023-12-02","hemoglobin_g_dL":12.7,"wbc_k_uL":6.1,"platelets_k_uL":335,"creatinine_mg_dL":1.25,"alt_U_L":56},{"date":"2024-08-08","hemoglobin_g_dL":12.7,"wbc_k_uL":5.1,"platelets_k_uL":299,"creatinine_mg_dL":1.13,"alt_U_L":64},{"date":"2025-04-10","hemoglobin_g_dL":11.6,"wbc_k_uL":7.4,"platelets_k_uL":162,"creatinine_mg_dL":1.57,"alt_U_L":35}]}
|
{"patient_id":"ANODE_SYNTH_2025_093","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":14.9,"microsatellite_status":"MSS","pd_l1_tps_percent":6},"baseline_clinical":{"age":59,"sex":"female","bmi":37.3,"smoking_pack_years":27,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":5.3,"metastatic_sites":["liver"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-07-10","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-19,"peak_response_20wk_change_percent":-72},"pfs_months":5.62},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-25","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":11.8,"censored":false},"longitudinal_labs":[{"date":"2025-06-19","hemoglobin_g_dL":11.5,"wbc_k_uL":8.8,"platelets_k_uL":448,"creatinine_mg_dL":0.77,"alt_U_L":44},{"date":"2026-01-06","hemoglobin_g_dL":10.3,"wbc_k_uL":4.0,"platelets_k_uL":358,"creatinine_mg_dL":1.28,"alt_U_L":89},{"date":"2026-01-25","hemoglobin_g_dL":11.7,"wbc_k_uL":7.6,"platelets_k_uL":274,"creatinine_mg_dL":1.63,"alt_U_L":33}]}
|
{"patient_id":"ANODE_SYNTH_2025_094","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"KRAS G12C","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":12.6,"microsatellite_status":"MSS","pd_l1_tps_percent":10},"baseline_clinical":{"age":52,"sex":"male","bmi":35.8,"smoking_pack_years":76,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["liver","contralateral lung","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"sotorasib 960 mg daily","start_date":"2025-06-20","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-56},"pfs_months":26.68},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2027-10-26","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":34.7,"censored":false},"longitudinal_labs":[{"date":"2025-04-17","hemoglobin_g_dL":12.6,"wbc_k_uL":8.8,"platelets_k_uL":198,"creatinine_mg_dL":0.86,"alt_U_L":44},{"date":"2025-12-17","hemoglobin_g_dL":12.4,"wbc_k_uL":4.7,"platelets_k_uL":187,"creatinine_mg_dL":1.21,"alt_U_L":64},{"date":"2027-10-26","hemoglobin_g_dL":12.7,"wbc_k_uL":3.2,"platelets_k_uL":177,"creatinine_mg_dL":1.84,"alt_U_L":132}]}
|
{"patient_id":"ANODE_SYNTH_2025_095","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":3.3,"microsatellite_status":"MSS","pd_l1_tps_percent":34},"baseline_clinical":{"age":61,"sex":"female","bmi":29.5,"smoking_pack_years":0,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":7.4,"metastatic_sites":["pleura","contralateral lung","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-03-15","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-63},"pfs_months":29.11},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2025-10-14","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":41.2,"censored":false},"longitudinal_labs":[{"date":"2023-01-25","hemoglobin_g_dL":14.4,"wbc_k_uL":6.8,"platelets_k_uL":172,"creatinine_mg_dL":0.97,"alt_U_L":70},{"date":"2023-09-11","hemoglobin_g_dL":13.2,"wbc_k_uL":4.8,"platelets_k_uL":158,"creatinine_mg_dL":0.98,"alt_U_L":32},{"date":"2025-10-14","hemoglobin_g_dL":12.3,"wbc_k_uL":4.6,"platelets_k_uL":256,"creatinine_mg_dL":1.91,"alt_U_L":91}]}
|
{"patient_id":"ANODE_SYNTH_2025_096","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"EGFR L858R","t790m_resistance":false,"tumor_mutational_burden_mut_Mb":14.2,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":64,"sex":"female","bmi":26.2,"smoking_pack_years":0,"ecog_performance_status":2,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":4.2,"metastatic_sites":["liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"osimertinib 80 mg daily","start_date":"2023-10-13","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-43,"peak_response_20wk_change_percent":-51},"pfs_months":25.69},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-01-21","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":45.4,"censored":true},"longitudinal_labs":[{"date":"2023-09-06","hemoglobin_g_dL":14.5,"wbc_k_uL":5.1,"platelets_k_uL":188,"creatinine_mg_dL":0.62,"alt_U_L":65},{"date":"2024-04-10","hemoglobin_g_dL":10.8,"wbc_k_uL":3.9,"platelets_k_uL":248,"creatinine_mg_dL":1.03,"alt_U_L":112},{"date":"2026-01-21","hemoglobin_g_dL":10.7,"wbc_k_uL":5.9,"platelets_k_uL":298,"creatinine_mg_dL":1.5,"alt_U_L":89}]}
|
{"patient_id":"ANODE_SYNTH_2025_097","cancer_type":"Non-small cell lung cancer","histology":"Squamous cell carcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"None (PD-L1 high)","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":9.5,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":77,"sex":"female","bmi":27.1,"smoking_pack_years":56,"ecog_performance_status":1,"comorbidities":[]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["contralateral lung","pleura","brain"],"brain_metastases_present":true,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"carboplatin + pemetrexed + pembrolizumab","start_date":"2024-09-05","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-12,"peak_response_20wk_change_percent":-52},"pfs_months":21.03},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-06-14","best_response":"Stable disease","toxicity_grade":["Grade 2 anemia","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":25.0,"censored":false},"longitudinal_labs":[{"date":"2024-07-18","hemoglobin_g_dL":14.0,"wbc_k_uL":10.5,"platelets_k_uL":356,"creatinine_mg_dL":0.87,"alt_U_L":78},{"date":"2025-03-04","hemoglobin_g_dL":12.7,"wbc_k_uL":5.7,"platelets_k_uL":293,"creatinine_mg_dL":1.1,"alt_U_L":69},{"date":"2026-06-14","hemoglobin_g_dL":10.3,"wbc_k_uL":5.7,"platelets_k_uL":174,"creatinine_mg_dL":1.07,"alt_U_L":82}]}
|
{"patient_id":"ANODE_SYNTH_2025_098","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":13.5,"microsatellite_status":"MSS","pd_l1_tps_percent":14},"baseline_clinical":{"age":56,"sex":"female","bmi":31.6,"smoking_pack_years":15,"ecog_performance_status":1,"comorbidities":["hyperlipidemia","COPD"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.8,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-08-18","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-39,"peak_response_20wk_change_percent":-43},"pfs_months":43.89},"second_line_therapy":{"trigger_reason":"radiologic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-04-25","best_response":"Stable disease","toxicity_grade":["Grade 1 nausea","none"]}},"survival_outcomes":{"overall_survival_months":75.6,"censored":false},"longitudinal_labs":[{"date":"2022-07-06","hemoglobin_g_dL":15.3,"wbc_k_uL":5.2,"platelets_k_uL":307,"creatinine_mg_dL":1.26,"alt_U_L":68},{"date":"2023-02-14","hemoglobin_g_dL":12.3,"wbc_k_uL":8.6,"platelets_k_uL":296,"creatinine_mg_dL":0.74,"alt_U_L":81},{"date":"2026-04-25","hemoglobin_g_dL":10.5,"wbc_k_uL":7.0,"platelets_k_uL":237,"creatinine_mg_dL":1.97,"alt_U_L":92}]}
|
{"patient_id":"ANODE_SYNTH_2025_099","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IVB","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":7.8,"microsatellite_status":"MSS","pd_l1_tps_percent":5},"baseline_clinical":{"age":57,"sex":"female","bmi":30.3,"smoking_pack_years":75,"ecog_performance_status":1,"comorbidities":["hyperlipidemia"]},"disease_burden_at_dx":{"primary_tumor_size_cm":3.7,"metastatic_sites":["bone","brain","pleura"],"brain_metastases_present":false,"radiology_summary":"PET-CT showed hypermetabolic primary mass with metastatic deposits; no intracranial disease."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2022-12-04","best_response":"Stable disease","radiologic_response":{"first_ct_8wk_change_percent":-37,"peak_response_20wk_change_percent":-36},"pfs_months":40.8},"second_line_therapy":{"trigger_reason":"new brain metastases","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2026-05-04","best_response":"Stable disease","toxicity_grade":["none","Grade 1 nausea"]}},"survival_outcomes":{"overall_survival_months":60.3,"censored":false},"longitudinal_labs":[{"date":"2022-11-07","hemoglobin_g_dL":15.2,"wbc_k_uL":7.2,"platelets_k_uL":243,"creatinine_mg_dL":1.0,"alt_U_L":70},{"date":"2023-06-02","hemoglobin_g_dL":11.8,"wbc_k_uL":6.7,"platelets_k_uL":320,"creatinine_mg_dL":1.25,"alt_U_L":28},{"date":"2026-05-04","hemoglobin_g_dL":12.5,"wbc_k_uL":5.7,"platelets_k_uL":208,"creatinine_mg_dL":0.82,"alt_U_L":99}]}
|
{"patient_id":"ANODE_SYNTH_2025_100","cancer_type":"Non-small cell lung cancer","histology":"Adenocarcinoma","stage_at_diagnosis":"IV","molecular_profile":{"driver_mutation":"ALK fusion","t790m_resistance":null,"tumor_mutational_burden_mut_Mb":11.9,"microsatellite_status":"MSS","pd_l1_tps_percent":23},"baseline_clinical":{"age":52,"sex":"male","bmi":34.1,"smoking_pack_years":42,"ecog_performance_status":1,"comorbidities":["hypertension"]},"disease_burden_at_dx":{"primary_tumor_size_cm":6.0,"metastatic_sites":["pleura","liver","bone"],"brain_metastases_present":true,"radiology_summary":"PET-CT + brain MRI confirmed extracranial metastases; asymptomatic brain metastases present."},"treatment_course":{"first_line_therapy":{"regimen":"alectinib 600 mg BID","start_date":"2020-12-28","best_response":"Partial response","radiologic_response":{"first_ct_8wk_change_percent":-26,"peak_response_20wk_change_percent":-51},"pfs_months":26.25},"second_line_therapy":{"trigger_reason":"symptomatic progression","regimen":"carboplatin (AUC5) + pemetrexed 500 mg/m\u00b2 q21d + pembrolizumab","start_date":"2023-04-06","best_response":"Stable disease","toxicity_grade":["none","Grade 2 anemia"]}},"survival_outcomes":{"overall_survival_months":53.4,"censored":false},"longitudinal_labs":[{"date":"2020-12-08","hemoglobin_g_dL":14.5,"wbc_k_uL":10.2,"platelets_k_uL":428,"creatinine_mg_dL":0.66,"alt_U_L":43},{"date":"2021-06-26","hemoglobin_g_dL":13.3,"wbc_k_uL":9.0,"platelets_k_uL":180,"creatinine_mg_dL":1.14,"alt_U_L":32},{"date":"2023-04-06","hemoglobin_g_dL":12.6,"wbc_k_uL":3.1,"platelets_k_uL":343,"creatinine_mg_dL":1.61,"alt_U_L":60}]}
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 9